These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 33402201)
41. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O; Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247 [TBL] [Abstract][Full Text] [Related]
42. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949 [TBL] [Abstract][Full Text] [Related]
43. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. Hatashita S; Yamasaki H PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136 [TBL] [Abstract][Full Text] [Related]
44. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627 [TBL] [Abstract][Full Text] [Related]
45. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW; Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697 [TBL] [Abstract][Full Text] [Related]
48. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease. Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW; J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335 [TBL] [Abstract][Full Text] [Related]
49. Linking white matter hyperintensities to regional cortical thinning, amyloid deposition, and synaptic density loss in Alzheimer's disease. Zhang J; Chen H; Wang J; Huang Q; Xu X; Wang W; Xu W; Guan Y; Liu J; Wardlaw JM; Deng Y; Xie F; Li B Alzheimers Dement; 2024 Jun; 20(6):3931-3942. PubMed ID: 38648354 [TBL] [Abstract][Full Text] [Related]
50. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study. Kim JW; Byun MS; Yi D; Lee JH; Ko K; Jeon SY; Sohn BK; Lee JY; Kim YK; Shin SA; Sohn CH; Lee DY; PLoS Med; 2020 Feb; 17(2):e1003022. PubMed ID: 32097439 [TBL] [Abstract][Full Text] [Related]
52. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease. Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539 [TBL] [Abstract][Full Text] [Related]
53. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813 [TBL] [Abstract][Full Text] [Related]
54. Hippocampal subregional volume changes in elders classified using positron emission tomography-based Alzheimer's biomarkers of β-amyloid deposition and neurodegeneration. Busatto Filho G; Duran FLS; Squarzoni P; Coutinho AMN; Rosa PGP; Torralbo L; Pachi CGDF; da Costa NA; Porto FHG; Carvalho CL; Brucki SMD; Nitrini R; Forlenza OV; Leite CDC; Buchpiguel CA; de Paula Faria D J Neurosci Res; 2021 Feb; 99(2):481-501. PubMed ID: 33073383 [TBL] [Abstract][Full Text] [Related]
55. The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An Li J; Huang Q; Qi N; He K; Li S; Huang L; Pan F; Ren S; Hua F; Huang Y; Guan Y; Guo Q; Zhao J; Xie F J Cereb Blood Flow Metab; 2024 Jul; 44(7):1199-1207. PubMed ID: 38295871 [TBL] [Abstract][Full Text] [Related]
56. Early detection of amyloid load using Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598 [TBL] [Abstract][Full Text] [Related]
57. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269 [TBL] [Abstract][Full Text] [Related]
58. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem. Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262 [TBL] [Abstract][Full Text] [Related]
59. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease. Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265 [TBL] [Abstract][Full Text] [Related]